Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea

Feb 24, 2026Blood advances

Immune responses to COVID-19 vaccine in sickle cell patients taking hydroxyurea

AI simplified

mRNA Technology on OpenScience ↗PubMed ↗DOI ↗

Abstract

Patients with sickle cell disease may have impaired vaccine-induced immunity, contributing to their increased risk of COVID-19-related mortality.

Humoral and cellular immune responses in patients with sickle cell disease after COVID-19 mRNA vaccinations were similar to those of healthy individuals.
Despite similar antibody concentrations and T cell frequencies, type 1 cytokine production by spike-specific T cells was reduced in patients with sickle cell disease.
Higher serum fetal hemoglobin levels were associated with reduced cytokine and antibody production.
A third vaccination improved neutralizing antibody and memory B-cell responses, but T helper 1 cytokine production remained lower compared to controls.
Findings suggest delayed or reduced vaccine-induced immunity in patients with sickle cell disease.

AI simplified

Patients with sickle cell disease (SCD) are at increased risk of COVID-19-related mortality compared with healthy individuals, even after vaccination. To what extent impaired vaccine-induced immunity contributes to this risk is unknown. We prospectively investigated vaccine immunogenicity in 31 patients with SCD who received COVID-19 mRNA vaccines. All patients used hydroxyurea. We quantified humoral and cellular immune responses 4 weeks after the second and third vaccinations and compared the results with those of age-, sex-, and vaccine-matched healthy individuals. Irrespective of higher naïve and lower memory B-cell subsets, serum neutralizing spike glycoprotein 1 immunoglobulin G antibody concentrations and frequencies of spike-specific memory B cells were similar to those in healthy individuals at each time point. Frequencies of CD4+ and CD8+ T cells in patients with SCD were also comparable with controls; however, type 1 cytokine production by spike-specific T cells was reduced. Reduced cytokine production and lower antibody production correlated with higher serum fetal hemoglobin levels, suggesting an association with hydroxyurea use. Although a third vaccination improved neutralizing antibody and memory B-cell responses, T helper 1 cytokine production tended to remain lower in patients than in controls. Our data point toward delayed or reduced vaccine-induced immunity, in line with previous reports, which may contribute to the increased risk of COVID-19-related mortality reported in these patients. This trial was registered at www.ccmo.nl as NL-OMON51241.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text ↗

Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief